N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易_老虎社区_美港股上老虎

N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易

美股速递2025-09-26

N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法，重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1195339865?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-26 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195339865","market":"us","top_or_hot":-1,"title":"N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易","media":"美股速递","content":"<p>N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法，重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nN2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2025-09-26 04:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法，重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NITO","symbol_name":"N2OFF, Inc","start_time":0,"source_url":"","article_id":"1195339865","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195339865","pubTimestamp":1758830597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法，重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NITO":"N2OFF, Inc","BK4007":"制药","BK4093":"化肥与农用药剂","SPRC":"SciSparc Ltd.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"N2OFF, Inc shareholders approve merger deal with company focused on drug-resistant cancer drug development","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NITO":1,"SPRC":1},"content_text":"N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法，重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}